Shattuck Q1 net loss $18.5M, cash $114.6M; expects data at EHA June 2024

Shattuck Labs, Inc.

2024-Q1 EPS reported -$0.37 revenue$1,115,000

Net loss $18.5M ($0.37 per share) vs $20.7M ($0.49) in Q1 2023; R&D $16.3M, G&A $4.9M.
Cash and investments $114.6M at March 31, 2024, down from $135.5M a year ago; cash runway into 2026.
Phase 1B expansion for TP53m AML completed enrollment; randomized HR-MDS cohort expected Q2 2024; data at EHA June 2024.
Appointed Clay Siegall, Ph.D., and Kate Sasser, Ph.D. to Board of Directors effective March 1, 2024.
Entered collaboration with Ono Pharma for bifunctional fusion proteins in autoimmune/inflammatory diseases.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Shattuck Labs, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $18.5 million for the quarter ended March 31, 2024, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share.

Period: the quarter ended March 31, 2024
Net income: Net loss was $18.5 million for the quarter ended March 31, 2024, or $0.37 per basic and diluted share
EPS: $0.37 per basic and diluted share
Result: reported results

Exact text from the filing

Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended March 31, 2024 and provided recent business highlights.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Shattuck Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001680367-24-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.